SWEDEN - May 27, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, today announced a major milestone with more than 300,000 Nevisense melanoma detection tests used on patients globally. Nevisense is the only FDA Approved and CE Mark non-invasive diagnostic technology used by dermatologists to assess suspicious moles and better determine a patient's individual risk of melanoma, supporting more accurate and personalized decision-making at the point of care.
"We are excited by this milestone, which we believe is a testament to our shared desire with the melanoma healthcare community to improve the lives of patients," said Pia Renaudin, CEO, SciBase. "With every Nevisense test, we aim to enable clinicians to make more informed, more precise early detection decisions that can significantly improve patient outcomes."
About Nevisense
Designed to augment the capabilities of traditional dermoscopy, Nevisense leverages the unique electrical properties of skin tissue to provide clinicians with objective data to support their clinical assessment. The device delivers personalized results that help guide risk-aligned management strategies for patients with potentially malignant skin lesions.
With over 60 peer-reviewed clinical publications and studies, Nevisense has been shown to improve diagnostic accuracy and support improved patient outcomes. Its non-invasive method enables more efficient biopsy management decisions while ensuring that high-risk cases receive timely attention.
As the global burden of melanoma continues to rise, technologies like Nevisense are proving invaluable in aiding early detection efforts-where outcomes are most favorable.
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 17 June 2025 at 10:00 CEST at Advokatfirman Schjødt, Hamngatan 27, in Stockholm. The registration to the meeting will open at 9.30 CEST.
This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail.
Right to participate and notice of participation
A shareholder who wishes to participate at the general meeting must:
(i)
be recorded in the share register maintained by Euroclear Sweden AB on 9 June 2025, and
(ii)
notify the Company of its intention to participate by post to Advokatfirman Schjødt, attn: William Hellsten, Box 715, 101 33 Stockholm, or by e-mail to [email protected], no later than on 11 June 2025. The notification shall include full name, personal identification number or corporate registration number, address, telephone number, shareholding and, if applicable, information about assistants (not more than two).
Nominee-registered shares
Shareholders whose shares are held in the name of a nominee must, in order to be able to participate at the general meeting and exercise their voting right, temporarily re-register the shares in their own name in the share register maintained by Euroclear Sweden AB (so-called voting right registration). When preparing the share register for the general meeting as of the record date, 9 June 2025, voting right registrations completed by the nominee no later than on 11 June 2025 will be considered. This means that the shareholders must request that the nominee completes such voting right registration well in advance of 11 June 2025.
Participation by proxy
Shareholders represented by proxy must issue a power of attorney for the proxy. If the power of attorney is issued by a legal entity, a copy of the legal entity's certificate of registration, showing who has authority to issue the power of attorney, must be enclosed. The original version of the power of attorney and, if applicable, the certificate of registration, should well in advance of the general meeting, be sent by post to Advokatfirman Schjødt, attn: William Hellsten, Box 715, 101 33 Stockholm, or by e-mail to [email protected]. The power of attorney must not be older than one year unless a longer validity term (however not longer than five years) is specifically stated in the power of attorney. A proxy form is available on the Company's website, www.scibase.com.
Proposed agenda
Opening of the meeting.
Election of chairman of the meeting.
Preparation and approval of the voting list.
Approval of the agenda.
Election of one person who shall approve the minutes of the meeting.
Determination of whether the meeting has been duly convened.
Presentation of the annual report and the auditor’s report as well as of the consolidated financial statements and the auditor’s report on the group.
Resolution on:
adoption of the profit and loss statement and the balance sheet as well as of the consolidated profit and loss statement and the consolidated balance sheet;
allocation of the Company’s profit or loss according to the adopted balance sheet; and
discharge from liability for the members of the board of directors’ and the CEO.
Determination the number of members and deputies of the board of directors and number of auditors.
Determination of the remuneration to the members of the board of directors and the auditors.
Election of board members and auditor.
Resolution on principles for the appointment of the nomination committee.
Resolution on implementation of stock option program, directed issue of warrants and approval of transfer of warrants to fulfil the Company's commitments under the stock option program.
Resolution on amendments to the articles of association.
Resolution to authorise the board of directors to resolve on issuances of shares, warrants and/or convertible debentures.
Closing of the meeting.
THE NOMINATION COMMITTEE'S PROPOSED RESOLUTIONS
The nomination committee is composed of the chairman of the board of directors of the Company (i.e. Jesper Høiland), Anders Bladh (appointed by Ribbskottet AB), Fredrik Mattsson (appointed by Ejendals AB), and Dharminder Chahal (appointed by VanHerk Group) (the "Nomination Committee"). The Nomination Committee has presented the following proposed resolutions in relation to items 9-12 in the proposed agenda.
Determination the number of members and deputies of the board of directors and number of auditors, election of board members and auditor and determination of remuneration to the board members and auditor (items 9-11)
The Nomination Committee proposes that the board of directors, until the end of the next annual general meeting, shall consist of four (4) ordinary members without deputy members. Furthermore, it is proposed that a registered accounting firm shall be elected as auditor.
The Nomination Committee furthermore proposes that the remuneration to the board of directors, for the period until the end of the next annual general meeting, shall be SEK 404,000 (SEK 404,000) for the chairman of the board of directors and SEK 135,000 (SEK 135,000) to each of the other ordinary board members (who are not employed by a larger shareholder in the Company). The Nomination Committee further proposes that the Company’s auditor shall be paid in accordance with approved invoice.
The Nomination Committee proposes that Jesper Høiland, Robert Molander and Diana Ferro are re-elected, and that Anna Eriksrud is newly elected, as ordinary board members, all for the period until the end of the next annual general meeting. Furthermore, Jesper Høiland is proposed to be re-elected as chairman of the board of directors. Thomas Taapken has declined re-election.
The registered accounting firm PricewaterhouseCoopers AB (PwC) is proposed to be re-elected as auditor. The accounting firm has informed that Magnus Lagerberg will remain as principally responsible auditor.
Below is a summarised description of the proposed new board member. Information about all proposed board members will be made available on the Company’s website.
Anna Eriksrud
Education: Bachelor of Science (BSc) in Business Administration and Economics, Uppsala University.
Experience: Anna has over 40 years of experience in the pharmaceutical industry as well as medical technology from mainly international work in the EU, USA, China and Japan. She has been involved in taking drugs from project status to blockbuster in the US, worked with orphan drug products for special diseases as well as consumer-driven products. Her entrepreneurial spirit in Life Science was realized by building a "Speciality Pharmacy", Apotekssamariten, when the Swedish reform allowed it in 2019. Companies where Anna has worked (including product launches, as CEO/General Manager, with IPO and then list change) include Pharmacia, Leiras/Schering, QMED (Galderma) and NeoDynamics. Anna has been stationed for several years in the Netherlands, the United States and the United Kingdom.
Other current significant assignments: Chairman of the Board in Prosperum Vitae AB and Board member in AcuCort AB.
Shareholding: -
Independence: Anna is independent in relation to the Company and its management as well as to the Company's major shareholders.
Resolution on principles for the appointment of the nomination committee (item 12)
The Nomination Committee proposes the following principles for appointment of the nomination committee ("Nomination Committee Instruction").
The nomination committee shall consist of four members. The chairperson of the Board shall contact the three largest shareholders/shareholder constellations by voting rights, as per the end of the third quarter each year. These will be asked to appoint one member each who, together with the chairperson of the board, shall constitute the nomination committee.
Should any of the shareholders/shareholder constellations refrain from appointing a member, the next shareholder/shareholder constellation shall be approached until three members have been appointed, or until all shareholders/ shareholder constellations owning over 5% of the shares of the Company have been approached. If four members cannot be appointed as per the above, the nomination committee may consist of only three members.
The chairperson of the Company shall summon the members to a constituting meeting.
The composition of the nomination committee shall be published no later than six months ahead of the annual general meeting. The nomination committee’s mandate lasts until a new nomination committee has been constituted. The nomination committees shall appoint a chairperson representing one of the shareholders/shareholder constellations.
Should a member leave, a successor shall be appointed by the same shareholder/ shareholder constellation. Should a shareholder/shareholder constellation having appointed a member, significantly reduce their ownership in the Company, the next shareholder/ shareholder constellation in size shall be offered the opportunity to appoint a member, provided the nomination committee so decides.
Ahead of the annual general meeting, the nomination committee shall propose the following:
Chairperson at the annual general meeting,
The number of board members and potential deputy board members,
Potential committees and number of members,
The number of auditors and potential deputy auditors
Members, chairperson, potential deputy chairperson and potential deputy members,
Potential committee members and chairpersons,
Auditor and potential deputy auditors,
Remuneration to the board, split between chairperson, potential deputy chairperson and members,
Remuneration to committees, split between the chairperson and the members,
Remuneration to the auditor(s), and
Potential proposals for changes to this Nomination Committee Instruction.
The proposals of the nomination committee shall be presented in connection with the publishing of the annual general meeting or such other shareholder meeting where board or auditor appointments take place, as well as on the Company’s webpage, however not later than one month ahead of the shareholder meeting in question.
The Nomination Committee Instruction shall apply until a resolution regarding change of the procedure for nominating the nomination committee is resolved by the general meeting.
THE BOARD OF DIRECTORS' PROPOSED RESOLUTIONS
Allocation of the Company’s profit or loss according to the adopted balance sheet (item 8 (ii))
The board of directors proposes that no dividend shall be paid for the financial year 2024 and that the year's result shall be carried forward.
Resolution on implementation of stock option program, directed issue of warrants and approval of transfer of warrants to fulfil the Company's commitments under the stock option program (item 13)
The board of directors proposes that the general meeting resolves on:
implementation of a stock option program for employees in the United States - stock option program 2025/2029; and
hedging arrangements in respect of the stock option program 2025/2029, consisting of a directed issue of warrants and approval to transfer the warrants.
Objectives and reasons for the proposal
Following an evaluation, the board of directors has decided to propose to the general meeting the establishment of a new incentive program for current employees in the United States based on stock options. The purpose of the stock option program 2025/2029 is to reward long term commitments of employees in the United States in the SciBase group, to ensure that the Company's long term value increase is reflected in the remuneration for the participants of the program, to contribute to the capability to retain competent co-workers and to otherwise increase shared incentives between the group's employees and the Company's shareholders. In view of the terms proposed below, the size of the allotment and other circumstances, the board of directors assesses that the stock option program 2025/2029 is well-balanced and that it will be beneficial for the Company and its shareholders.
To secure the Company's commitments under the stock option program 2025/2029, the board of directors also proposes that the general meeting resolves on a directed issue of warrants and to approve the transfer of warrants in accordance with item B below.
A)Proposed resolution regarding implementation of stock option program 2025/2029
The board of directors proposes that the general meeting resolves to implement stock option program 2025/2029 according to the following main principles:
Stock option program 2025/2029 shall include not more than 1,000,000 stock options.
Each stock option hall entitles the holder to subscribe for one (1) new share in the Company at a subscription price corresponding to 120 per cent of the volume-weighted average price according to Nasdaq First North Growth Market’s official price list for the share during the ten trading days immediately preceding the annual general meeting, however not lower than the share's quota value. The subscription price and the number of shares for which each stock option entitles the holder to subscribe for may be subject to recalculation pursuant to a bonus issue, share split, new issue with preferential rights and similar measures, whereby conventional terms and conditions for recalculation shall be applied.
Stock option program 2025/2029 shall comprise the following categories of employees, whereby no participant is entitled to a minimum allotment.
Category
Maximum number of stock options per person
Key employees in the United States (maximum of 1 person)
600,000
Other employees in the United States (maximum of 4 persons)
150,000
The options granted per participant will depend on the position within the SciBase group.
Annual vesting will be determined by the board of directors in connection with the adoption of the year-end report for the financial years 2025, 2026 and 2027, respectively.
Options granted will vest by 1/3 during each of the financial years 2026, 2027 and 2028, based on performance and continued employment, or assignment, in the SciBase group. Vesting shall be proportional in relation to the period of employment or assignment during the year in question.
The reason for the vesting period being shorter than three years is that the Company is, in the near term, facing a period containing important milestones that are crucial for the Company’s short- and long-term development. According to the board of directors, it is therefore in the interest of the Company and its shareholders to apply a vesting period shorter than three years. However, in accordance with what is stated below, any vested stock options may not be exercised before 2029, which exceeds three years.
The stock options will be allotted free of charge. Such offers must be made within 10 business days of the decision to allotment being made. Over-allocation cannot take place.
The holder shall be entitled to exercise the stock options during the periods set out below, provided that the performance criteria for vesting is fulfilled. The performance criteria for vesting will be based on fixed technical milestone-criteria in projects, criteria for development of the project portfolio and other pre-determined criteria attributable to the business. The performance criteria are designed to promote the long-term value creation of the Company.
The holders may exercise vested stock options as from the day of release of the Company’s year-end report for the financial year 2028 up to and including 30 June 2029.
Upon exercise, each stock option will entitle the holder to receive one warrant immediately exercisable for one share in the Company against payment of the subscription price.
For participation in stock option program 2025/2029 it is required that such participation is legally possible, and that such participation is possible at reasonable administrative costs and with reasonable financial resources.
Issued stock options do not constitute securities and may not be transferred, pledged or otherwise disposed of by the holder.
In other respects, the board of directors shall establish the general terms for participation in the program.
B) Directed issue of warrants and approval of transfer of warrants to secure the Company's commitments under stock option program 2025/2029
To enable the Company's delivery of shares pursuant to stock option program 2025/2029 the board of directors proposes that the general meeting resolves on a directed issue of warrants and to approve the transfer of warrants on the following terms:
A maximum of 1,000,000 warrants shall be issued, entailing an increase in the share capital of a maximum of SEK 50,000.00.
The right to subscribe for the warrants shall, with deviation from the preferential right for existing shareholders, vest in SciBase Holding AB (publ), reg. no. 556773-4768.
Subscription of the warrants shall be made on a separate subscription list no later than three weeks after the resolution on issue of warrants. The board of directors shall be entitled to extend the subscription period.
The warrants shall be issued free of charge.
Each warrant shall entitle the holder to subscribe for one (1) new share in the Company.
Each warrant shall entitle the holder to subscribe for one (1) new share in the Company at a subscription price corresponding to 120 per cent of the volume-weighted average price according to Nasdaq First North Growth Market’s official price list for the share during the ten trading days immediately preceding the annual general meeting, however not lower than the share's quota value. The subscription price and the number of shares for which each stock option entitles the holder to subscribe may be subject to recalculation pursuant to a bonus issue, share split, new issue with preferential rights and similar measures, whereby conventional terms and conditions for recalculation shall be applied.
Subscription of shares by virtue of the warrants may be made as from the day of release of the Company's year-end report for the financial year 2028 up to and including 30 June 2029.
Shares issued following exercise of warrants during a certain financial year shall entitle to dividend for the first time on the record day for dividend which occurs following registration of the shares with the Swedish Companies Registration Office.
The complete terms and conditions for the warrants are set out in "Terms and conditions for warrants of series 2025/2029 in SciBase Holding AB (publ)".
The reason for the deviation from the shareholders' preferential right is that the issue forms part of the implementation of stock option program 2025/2029. In view of what is set forth under Objectives and reasons for the proposal above, the board of directors is of the opinion that it is of benefit to the Company and its shareholders that certain employees in the USA are offered to participate in stock option program 2025/2029.
The board of directors further proposes that the general meeting resolves to approve that the Company transfers warrants to participants in stock option program 2025/2029.
Finally, the board of directors proposes that the board of directors, or anyone appointed by the board of directors, should be authorised to make such minor adjustments to the above proposal that may be necessary in connection with the registration procedures with the Swedish Companies Registration Office, and possible registration of the warrants with Euroclear Sweden AB.
Costs and effects on important key ratios
The option program 2025/2029 will lead to certain costs. Based on the assumption that 100 per cent of the options in the program will be vested, the salary cost in the accounts pursuant to IFRS 2 is expected to amount to approximately SEK 0.20 million in total during the period 2025-2029 based on the options actual value at the start of the program. The options have no market value as they are non-transferable. However, the board of directors has assessed a theoretical value of the options through application of the Black & Scholes valuation model. The calculations have been based on an assumed share price of SEK 0.41 and an assumed volatility of 70 per cent. The value of the options of option program 2025/2029 pursuant to this valuation is approximately SEK 0.20 per option with the application of the Black & Scholes formula. The transfer restrictions have not been taken into account in the valuation. The actual IFRS 2 cost during the vesting period depends on how many options that are vested.
At fulfilment of the vesting conditions and exercise of the options, option program 2025/2029 will lead to costs in the form of social security charges. The total costs for social security charges during the vesting period depends on how many options that are vested and the value of the options at exercise. Based on the assumption that 100 per cent of the options in the option program 2025/2029 will be vested, a subscription price of SEK 0.49 and an assumed share price of SEK 0.81 at the exercise of the options, the costs for social security charges will amount to approximately SEK 0.02 million. The Company’s total cost for social security charges is proposed to be hedged through a directed issue of warrants pursuant to item B above.
The board of directors deems that the positive effects on earnings that are expected to result from increased share ownership among employees in the USA, which may be further increased through the stock option program 2025/2029, outweighs the costs related to the stock option program 2025/2029.
The stock option program 2025/2029 is assessed to have a marginal impact on the Company's key figures.
Dilution
Upon full exercise of all stock options, 1,000,000 new shares in the Company can be issued, which corresponds to a dilution of approximately 0.3 percent of the total number of shares and votes in the Company, however, subject to any potential adjustment which may occur under the terms and conditions for the warrants. Accordingly, the program offers the employees the possibility to increase their shareholding in the Company to the corresponding figure.
Majority requirements
The board of directors’ proposal for a resolution regarding option program 2025/2029 and the necessary security measures connected thereto pursuant to items A and B above form one combined proposal. Therefore, it is proposed that the resolutions of the general meeting under item A and B are passed as one single resolution, pursuant to the majority provisions of chapter 16 of the Swedish Companies Act, meaning that shareholders holding not less than 9/10th of both the votes cast and the shares represented at the general meeting must vote for the proposal.
Preparation of the matter
The principles of stock option program 2025/2029 have been prepared by the board of directors of the Company. The board of directors has thereafter decided to submit this proposal to the general meeting. Except for the officials who prepared the matter pursuant to instructions from the board of directors, no employee that may be included in the program has taken part in the drafting thereof.
Other share-based incentive programs
The Company has no other ongoing share-based incentive programs.
Authorisation for the board of directors
The board of directors proposes that the general meeting authorises the board of directors to execute the resolutions in accordance with the above and to ensure the transfer of the warrants in accordance with the above.
Resolution on amendments to the articles of association (item 14)
The Board of Directors proposes that the general meeting resolves to amend the limits for the share capital and the number of shares in the Company's articles of association in accordance with the below.
§ 4 in the articles of association is proposed to have the following wording.
Proposed wording
The share capital shall amount to at least SEK 16,914,781.65 and not more than SEK 67,659,126.60.
§ 5 in the articles of association is proposed to have the following wording.
Proposed wording
The number of shares shall be not less than 338,295,633 and not more than 1,353,182,532.
The board of directors, the CEO, or anyone appointed by the board of directors or the CEO, shall be authorised to make such minor amendments to the above resolution as may be necessary in connection with the registration of the resolution with the Swedish Companies Registration Office or due to other formal requirements.
Majority requirements
A valid resolution requires that the resolution is supported by shareholders representing at least two thirds of the votes cast as well as of the shares represented at the general meeting.
Resolution to authorise the board of directors to resolve on issuances of shares, warrants and/or convertible debentures (item 15)
The board of directors proposes that the annual general meeting resolves to authorise the board of directors to, until the next annual general meeting, on one or more occasions, decide upon issuances of new shares, issuance of warrants and/or convertibles. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and may be made either in cash and/or by way of set-off or contribution in kind or otherwise be conditional. Through issuances resolved upon with support from the authorisation - with deviation from the shareholders' preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 30 percent dilution of the share capital and the number of shares and votes in the Company after such issue(s). The chairman of the board of directors, the CEO or a person appointed by the board of directors shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.
Majority requirements
A resolution in accordance with the proposal, item 15, is valid only when supported by shareholders holding not less than two thirds of both the votes cast and of the shares represented at the general meeting.
Documentation etc.
The annual report and the auditor's report, the board of directors' proposals and all other related documentation will be available at the Company's office and on the Company's website, www.scibase.se, no later than three weeks prior to the general meeting and will be sent free of charge to shareholders who so request and provide their postal address.
This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail.
Shareholders' right to request information
Shareholders are reminded of their right to request information from the board of directors and managing director in accordance with Chapter 7 Section 32 of the Swedish Companies Act.
Use of personal data
For information regarding the processing of your personal data, please see the integrity policy that is available at Euroclear Sweden AB's website: www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
_________________
Stockholm in May 2025 SciBase Holding AB (publ) The board of directors
Certified Advisor (CA): Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The cash flow from current operations was negative in the amount of TSEK 26,001 (13,182).
The gross margin was 70.5% (69.9%).
Electrode sales volume increased by 30% and was 17,870 (13,724) units. Repeat sales of electrodes to existing customers increased by 20%.
Important events during the quarter
Overall sales increased by 46% (+45%, before currency effects). Sales in Germany within the skin cancer segment increased by 14%(14% in local currency). Sales in the US skin cancer market increased by 306% (295% in local currency) while the sales within the skin barrier segment decreased by 10%.
SciBase announced that Mayo Clinic, the leading US hospital, will test Nevisense in a Pilot.
SciBase announced the final outcome of directed issue and rights issue.
Nevisense (EIS) included in updated German (S1) imaging guidelines and mentioend as a technology for detecting Melanoma and Non-Melanoma skin cancer.
SciBase continues to expand in the US, on-boarding Several US Dermatology Practices that Specialize in Skin Cancer Detection.
Important events after the end of the period
SciBase announced the launch of the next generation of Nevisense; Nevisense V.
Apr 1, 2024 -
Jan 1 -March 31
March 31, 2025
Jan 1 - Dec 31
THE GROUP
2025
2024
Rolling-12
2023
Net sales, SEK ths
8 856
6 057
32 503
29 705
Gross margin, %
70,5%
69,9%
71,0%
71,0%
Equity/Asset ratio, %
71,6%
58,2%
65,5%
59,4%
Net indebtness, multiple
0,40
0,72
0,53
0,68
Cash equivalents, SEK ths
34 295
20 272
34 295
11 245
Cashflow from operating activities, SEK ths
-26 001
-13 182
-70 203
-57 383
Earnings per share (before and after dilution), SEK
-0,09
-0,09
-0,35
-0,34
Shareholder's equity per share, SEK
0,14
0,25
0,16
0,21
Average number of shares, 000'*
298 710
119 831
222 713
177 994
Number of shares at closing of period, 000'*
338 296
119 831
338 296
219 538
Share price at end of period, SEK
0,42
0,39
0,42
0,41
Number of sold electrodes, pieces
17 870
13 724
66 356
62 210
Average number of employees
35
26
28
28
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 13, 2025.
This interim report report has not been subject to review by the Company’s auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SWEDEN - April 11, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, is proud to announce the launch of the next generation of Nevisense; Nevisense V.
The new platform features an updated user interface, enhanced display resolution, and an upgraded, more user-friendly touchscreen. Beyond these hardware enhancements, Nevisense V offers new features specifically designed for both skin cancer diagnostics and research applications.
"I am proud to announce the launch of our next generation of Nevisense," said Pia Renaudin, CEO of SciBase. "This newly released version includes several exciting features and enhancements. We have also strategically prepared the platform for future expansion into new markets and clinical indications.
With Nevisense V, SciBase continues its mission to advance noninvasive solutions that support earlier diagnosis and improved patient outcomes in dermatology.
Certified Advisor (CA): Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The cash flow from current operations was negative in the amount of TSEK 12,548 (17,352).
The gross margin was 68.5% (73.5%).
Electrode sales volume increased by 42% and was 17,132 (12,044) units. Repeat sales of electrodes to existing customers increased by 36%.
January - December in figures
Net sales were TSEK 29,705 (23,245), +28%.
The loss after tax was TSEK 61,125 (55,585).
The loss per share was SEK 0.34 (0.51).
The cash flow from current operations was negative in the amount of TSEK 57,383 (51,984).
The gross margin was 71.0% (69.0%).
Electrode sales volume increased by 20% and was 62,210 (51,920) units. Repeat sales of electrodes to existing customers increased by 16%.
Important events during the quarter
Overall sales increased by 49% (+49%, before currency effects). Sales in Germany within the skin cancer segment increased by 27%(26% in local currency). Sales in the US skin cancer market increased by 319% while the sales within the skin barrier segment decreased by 21%.
The Board decided on a directed issue of approximately SEK 22.5 million and a rights issue of up to approximately SEK 59.3 million. The capital raise was subsequently approved by an EGM on December 13, 2024 and a prospectus was published on December 20.
SciBase initiated sales collaboration in Italy.
An interesting case study highlighting the use of Nevisense as a skin barrier assessment device in monitoring treatment outcomes in patients with atopic dermatitis (AD) was published. The study, conducted by a team of researchers at Koç University in Istanbul, demonstrates the potential of Nevisense to revolutionize the way AD patients are treated and monitored.
A Nomination Committee has been appointed for SciBase Holding’s Annual General Meeting in 2025.
Important events after the end of the period
SciBase announced that Mayo Clinic, the leading US hospital, will test Nevisense in a Pilot.
SciBase announced the final outcome of directed issue and rights issue.
Nevisense (EIS) included in updated German (S1) imaging guidelines and mentioend as a technology for detecting Melanoma and Non-Melanoma skin cancer.
SciBase continues to expand in the US, on-boarding Several US Dermatology Practices that Specialize in Skin Cancer Detection.
Oct 1 - Dec 31
Jan 1 -Dec 31
THE GROUP
2024
2023
2024
2023
Net sales, SEK ths
8 598
5 764
29 705
23 245
Gross margin, %
68,5%
73,5%
71,0%
69,0%
Equity/Asset ratio, %
59,4%
66,9%
59,4%
66,9%
Net indebtness, multiple
0,68
0,49
0,68
0,49
Cash equivalents, SEK ths
11 245
34 121
11 245
34 121
Cashflow from operating activities, SEK ths
-12 548
-17 352
-57 383
-51 984
Earnings per share (before and after dilution), SEK
-0,08
-0,17
-0,34
-0,51
Shareholder's equity per share, SEK
0,17
0,36
0,21
0,40
Average number of shares, 000'*
219 538
119 831
177 994
107 980
Number of shares at closing of period, 000'*
219 538
119 831
219 538
119 831
Share price at end of period, SEK
0,41
0,83
0,41
0,83
Number of sold electrodes, pieces
17 132
12 044
62 210
51 920
Average number of employees
29
26
28
23
*Excluding BTA from ongoing new share issue
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 25, 2025.
This interim report report has not been subject to review by the Company’s auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
STOCKHOLM, SWEDEN, - February 21, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disordersannounced today, that an article comparing US and German dermatologists improved biopsy decisions following the addition of Nevisense (EIS) as a decision support tool was recently published in SKIN, the Journal of Cutaneous Medicine. The article compares two corresponding studies, one conducted in the US and one in Germany, with the aim to evaluate how Nevisense (EIS) impacted dermatologist's biopsy decisions. The findings were that for both groups the addition of dermoscopy and even more so Nevisense (EIS) as decision support tools significantly improved biopsy decision accuracy. Findings revealed that American dermatologists had a higher rate of correct biopsy decisions for malignant melanomas (MMs) compared to their German counterparts. However, German dermatologists showed greater accuracy in avoiding unnecessary biopsies of benign pigmented skin lesions.
The article further discusses the potential reasons for this difference between the countries and that practice patterns, training, and malpractice concerns (especially in the US) may explain the higher biopsy rates of benign lesions in the US. These results underscore the utility of EIS as a complementary tool to dermoscopy, enhancing the accuracy of biopsy decisions and improving patient outcomes
"It is an interesting article showing the positive effects of adding Nevisense and EIS as a decision support tool. Cultural differences can also be seen between German and US physicians where US dermatologist's are more afraid to miss a melanoma and therefore have a higher biopsy rate while in Germany they try to avoid unnecessary biopsies. The key message is that Nevisense can secure a better decision for the patient.", says Pia Renaudin, CEO of SciBase.
The article can be found here: https://skin.dermsquared.com/skin/article/view/3172
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, - January 30, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disordersannounced todaythat it has on-boarded several US dermatology practices that specialize in skin cancer detection, diagnosis and treatment. Through these US practices, SciBase will further their mission to improve outcomes for patients and clinicians by expanding access of the Nevisense test to additional states in the US.
"The innovative Nevisense test provides us the point-of-care capability in diagnosing melanoma at the earliest possible stage. This is extremely important for our patients because early-stage melanoma is almost 100% curable. Given that melanoma is the deadliest form of skin cancer with about 20 people dying of the disease per day in the US, early detection becomes critical to survival", said Dr. Michael McPhee, surgical oncologists, owner and managing director of the Melanoma Clinic in Orlando, Florida.
"To date, evaluating atypical moles at point-of-care to assess and guide biopsy decisions remains challenging, even for experienced dermoscopists. Early melanomas and even some invasive melanomas can have very few morphologic features, which make it challenging to assess at point-of-care. The Nevisense tests is non-invasive and provides us with important cellular data from below the skin surface before we make our biopsy decision, enabling improved atypical mole management for our patients", said Dr. Alison Z. Young, dermatologist and dermatopathologist, and owner of Young Dermatology in Seattle, Washington.
"SciBase is dedicated to its mission of empowering healthcare professionals to improve diagnostic accuracy, enable disease monitoring, and facilitate early intervention of skin cancer and skin disorders. We are pleased to be able to give our full support to clinicians like Dr. McPhee and Dr. Young who are deeply committed and focused on skin cancer patients", said Pia Renaudin, CEO of SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, - January 28, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disordersannounced today that a new review article has been published highlighting the performance of Nevisense in identifying malignant skin lesions. The article titled "Progressive approaches in oncological diagnosis and surveillance: real-time impedance-based techniques and advanced algorithms" was written by researchers at George Washington University, Washington DC, USA, and has been published in the journal "Bioelectromagnetics."
The review points to Nevisense's high sensitivity for detection of both melanoma and non-melanoma skin cancer, highlighting Nevisense as a valuable tool in identifying malignant skin lesions.
The overarching goal of the review is to summarize the clinical potential of state-of-the-art impedance-based technologies, explaining distinct electrical signatures inherent to cancer vs healthy tissues. These techniques offer real-time insights into tumor dynamics, paving the way for precision-guided therapeutic interventions.
The article is available through the following link: https://doi.org/10.1002/bem.22540
"This is an interesting review of important technologies for identifying different cancers. Nevisense represents an innovative approach to enhancing early-stage melanoma detection while minimizing unnecessary medical procedures through real-time impedance measurements," says Pia Renaudin, CEO of SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of units that was announced on November 12, 2024. Following the completed recalculation, SciBase can confirm that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share, remains unchanged. Thus, one (1) warrant of series TO 2 entitles the holder to subscribe for one (1) share at a subscription price of SEK 0.42, in accordance with the previously communicated terms and conditions for the warrants.
Each warrant of series TO 2 entitles the holder to subscribe for one (1) new share in the Company during the period April 3, 2029, until and including April 17, 2029. The subscription price for subscription of shares with the support of warrants of series TO 2 corresponds to SEK 0.42 per share.
The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website.
The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on January 27, 2025.
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The Company has been listed on Nasdaq First North Growth Market since June 2, 2015, and the Certified Advisor is Carnegie Investment Bank AB (publ). For more information, visit www.SciBase.com. All press releases and financial reports can be found here: http://investors.scibase.se/sv/pressmeddelanden.
